Clini Cancer Res: PD-L1 expression is associated with the prognosis of new complementary chemotherapy for triple-negative breast cancer.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- background: In the Keynote 522 trial in the context of metastasis, three-negative breast cancer (TNBC) patients benefited from PD-1 axis immunotherapy.therefore, the study used a quantitative immunohistometal method to detect the expression of PD-L1 in tumor cells and immune cells to assess the correlation between PD-L1 expression and the benefits of combined chemotherapy using new auxiliary defertilated in TNBC patients.method: Obtaining pre-treatment acupuncture biopsy tissue (n-69) in patients participating in Phase II clinical trials (NCT02489448), and 45 patients were finally analyzed according to the quality of the tissues (qCR?18, non-pCR-27).results: The expression of PD-L1 in pCR patients increased significantly compared to those with non-pCR.in pCR and non-pCR cases, there was no difference in the number of CD68-positive cells in tumor or interstitial chambers: PD-L1 was expressed in tumor cells, interstitial immune cells, and co-located with CD68-positive cells, associated with high pCR rates in TNBC patients with dalsating monotomachecklista chemotherapy therapy..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
